277 related articles for article (PubMed ID: 30612319)
1. Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice.
Greenbaum C; VanBuecken D; Lord S
Drugs; 2019 Jan; 79(1):43-61. PubMed ID: 30612319
[TBL] [Abstract][Full Text] [Related]
2. Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes.
Greenbaum C; Lord S; VanBuecken D
Curr Diab Rep; 2017 Oct; 17(11):119. PubMed ID: 29039056
[TBL] [Abstract][Full Text] [Related]
3. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.
Insel RA; Dunne JL; Atkinson MA; Chiang JL; Dabelea D; Gottlieb PA; Greenbaum CJ; Herold KC; Krischer JP; Lernmark Å; Ratner RE; Rewers MJ; Schatz DA; Skyler JS; Sosenko JM; Ziegler AG
Diabetes Care; 2015 Oct; 38(10):1964-74. PubMed ID: 26404926
[TBL] [Abstract][Full Text] [Related]
4. Risk of beta-cell autoimmunity presence for progression to type 1 diabetes: A systematic review and meta-analysis.
Ling Q; Lu J; Li J; Xu Q; Zhu D; Bi Y
J Autoimmun; 2018 Jan; 86():9-18. PubMed ID: 28988642
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune markers in diabetes.
Winter WE; Schatz DA
Clin Chem; 2011 Feb; 57(2):168-75. PubMed ID: 21127152
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of β-cell antibodies and associated autoimmune diseases in children and adolescents with type 1 diabetes (T1DM) versus type 2 diabetes (T2DM) in Qatar.
Alyafei F; Soliman A; Alkhalaf F; Sabt A; De Sanctis V; Elsayed N; Waseef R
Acta Biomed; 2018 May; 89(S5):32-39. PubMed ID: 30049930
[TBL] [Abstract][Full Text] [Related]
7. Immunopathogenesis and immunotherapeutic approaches to type 1A diabetes.
Azam A; Eisenbarth GS
Expert Opin Biol Ther; 2004 Oct; 4(10):1569-75. PubMed ID: 15461568
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Molecules, Personalized Immunotherapy, and Autoimmune Diabetes.
Orabona C; Mondanelli G; Puccetti P; Grohmann U
Trends Mol Med; 2018 Nov; 24(11):931-941. PubMed ID: 30236470
[TBL] [Abstract][Full Text] [Related]
9. Sequential data mining of infection patterns as predictors for onset of type 1 diabetes in genetically at-risk individuals.
Mistry S; Gouripeddi R; Raman V; Facelli JC
J Biomed Inform; 2023 Jun; 142():104385. PubMed ID: 37169058
[TBL] [Abstract][Full Text] [Related]
10. Islet cell autoantibodies and insulin-dependent (type I) diabetes mellitus.
Yeo PP
Ann Acad Med Singap; 1985 Apr; 14(2):343-6. PubMed ID: 3898983
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapies and immune biomarkers in Type 1 diabetes: A partnership for success.
Rekers NV; von Herrath MG; Wesley JD
Clin Immunol; 2015 Nov; 161(1):37-43. PubMed ID: 26122172
[TBL] [Abstract][Full Text] [Related]
12. Regulation of autoimmune diabetes: characteristics of non-islet-antigen specific therapies.
Gazda LS; Baxter AG; Lafferty KJ
Immunol Cell Biol; 1996 Oct; 74(5):401-7. PubMed ID: 8912002
[TBL] [Abstract][Full Text] [Related]
13. Type I diabetes mellitus: a predictable autoimmune disease with interindividual variation in the rate of beta cell destruction.
Dotta F; Eisenbarth GS
Clin Immunol Immunopathol; 1989 Jan; 50(1 Pt 2):S85-95. PubMed ID: 2642771
[TBL] [Abstract][Full Text] [Related]
14. Prediction and prevention of type 1 diabetes: update on success of prediction and struggles at prevention.
Michels A; Zhang L; Khadra A; Kushner JA; Redondo MJ; Pietropaolo M
Pediatr Diabetes; 2015 Nov; 16(7):465-84. PubMed ID: 26202050
[TBL] [Abstract][Full Text] [Related]
15. Understanding childhood diabetes mellitus: new pathophysiological aspects.
Grulich-Henn J; Klose D
J Inherit Metab Dis; 2018 Jan; 41(1):19-27. PubMed ID: 29247329
[TBL] [Abstract][Full Text] [Related]
16. Diabetes type 1: Can it be treated as an autoimmune disorder?
Vallianou NG; Stratigou T; Geladari E; Tessier CM; Mantzoros CS; Dalamaga M
Rev Endocr Metab Disord; 2021 Dec; 22(4):859-876. PubMed ID: 33730229
[TBL] [Abstract][Full Text] [Related]
17. Type 1 Diabetes: Current Perspectives.
Kozhakhmetova A; Gillespie KM
Methods Mol Biol; 2016; 1433():1-9. PubMed ID: 26659804
[TBL] [Abstract][Full Text] [Related]
18. Disease-modifying immunotherapy for the management of autoimmune diabetes.
Castro CN; Barcala Tabarrozi AE; Noguerol MA; Liberman AC; Dewey RA; Arzt E; Morelli AE; Perone MJ
Neuroimmunomodulation; 2010; 17(3):173-6. PubMed ID: 20134195
[TBL] [Abstract][Full Text] [Related]
19. Emerging immune therapies in type 1 diabetes and pancreatic islet transplantation.
Schneider DA; Kretowicz AM; von Herrath MG
Diabetes Obes Metab; 2013 Jul; 15(7):581-92. PubMed ID: 23194064
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of diabetes-specific autoimmunity in first-degree relatives of Sardinian patients with type 1 diabetes.
Incani M; Serafini C; Satta C; Perra L; Scano F; Frongia P; Ricciardi R; Ripoli C; Soro M; Strazzera A; Zampetti S; Buzzetti R; Cavallo MG; Cossu E; Baroni MG
Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27726307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
